Agile therapeutics (AGRX) has had a, shall we say, crazy week in the market. On Monday, October 28, its share price was sent …
Shares of Agile Therapeutics (AGRX), a biotech which specializes in women’s healthcare, are in a nose dive, down about 66% in the past …
At just $68 million in market capitalization, Agile Therapeutics (AGRX) is anything but what you’d call “Big Pharma” — but it’s getting bigger. …
Even though Cantor’s William Tanner slices his price target, he nonetheless angles for almost 115% whopping upside potential for AGRX shares.
In a research report released today, William Blair analyst Tim Lugo reaffirmed an Outperform rating on Agile Therapeutics (NASDAQ:AGRX) with an $18 price …
In a research note released today, Janney Capital analyst Kimberly Lee reiterated a Buy rating on Agile Therapeutics (NASDAQ:AGRX) with an $18 fair value …
